How fast do weight loss injections actually work?

What the trial data says about early versus later change

The large phase-3 trials that underpinned UK licensing give the most reliable picture of how these medicines perform over time. In SURMOUNT-1, published in the New England Journal of Medicine, adults taking tirzepatide recorded an average body-weight reduction of around 20–21% at 72 weeks on the highest dose. That figure sounds dramatic. What the paper also shows is that change was front-loaded: the steepest slope on the weight curve came between roughly weeks 12 and 36, after doses had escalated to a meaningful level. The earliest weeks, when patients were on the 2.5mg starter dose, produced modest change. That's by design. The first pen's job is to let your digestive system adjust to the medicine, not to deliver rapid loss.

Semaglutide (Wegovy) follows a similar pattern. STEP 1 recorded around 15% average loss over 68 weeks at 2.4mg maintenance, again with the largest gains appearing after the titration phase was complete. The NHS medicines page for tirzepatide explains this dose escalation clearly and is worth reading alongside any trial summary. The practical lesson from both datasets: weeks one to four are about adjustment; months two to six are where most of the observable change tends to happen.

Individual variation is real and significant. Age, starting BMI, metabolic health, diet quality alongside treatment, and activity levels all affect the rate. Two people on the same dose at the same point in their titration can report noticeably different results. That's not a failure, it reflects genuine biological difference, and it's precisely why a prescriber reviews your case rather than a fixed algorithm doing so.

Why the early weeks feel slower than you might expect

It's completely understandable to feel impatient in the first month. You're taking an injection every week, adjusting to a new routine, and the scales might not be moving as fast as you hoped. That experience is normal and almost universal. The reason is structural: licensed GLP-1 medicines begin at a dose chosen specifically to minimise nausea and GI discomfort. Tirzepatide starts at 2.5mg; semaglutide starts at 0.25mg. Neither is the therapeutic maintenance dose.

What you're likely to notice in those early weeks is appetite change rather than dramatic scale movement. Many people find they feel full faster, stop thinking about food between meals, and eat smaller portions without much conscious effort. That shift in behaviour is the mechanism working, it just takes time for sustained lower intake to show up as significant weight change. If you're curious about the biological process behind this, our page on how weight loss injections work covers the GIP and GLP-1 receptor pathways in more detail.

Common side effects in early weeks, particularly nausea, diarrhoea and indigestion, are also most pronounced at this stage and tend to settle as your body adapts. If they don't ease, or if you experience severe persistent stomach pain that radiates to the back, seek medical help promptly, the MHRA highlighted acute pancreatitis as a known though infrequent risk in a Drug Safety Update published in January 2026. Mild GI discomfort is expected and usually brief; severe pain is a reason to contact a clinician.

How the pace of change shifts after six months

Once you reach your highest tolerated maintenance dose, typically somewhere between months two and four depending on your titration schedule, weight loss tends to continue but at a steadier pace. The steep early gradient flattens. This is normal physiology, not the treatment stopping. Your body is adapting to a lower set-point, and the hormonal signals that drove initial appetite suppression are doing ongoing work rather than dramatic acute work.

For context on the overall landscape of what's available and how the two licensed options compare on results, our overview of weight loss injections covers both medicines. If cost is part of your thinking, our cost context page explains what legitimate private pricing typically includes and why per-unit price comparisons between providers can be misleading.

NICE's appraisal of tirzepatide (TA1026) notes that treatment continuation at six months is reviewed if weight loss is less than 5% of starting body weight at the highest tolerated dose, a useful clinical benchmark to be aware of. If you're on treatment and concerned about your progress, that's a conversation for your prescriber, who can see your full picture.

What this means before you start

Going into treatment with a realistic timeline tends to lead to better outcomes. People who expect dramatic change in the first two weeks are most likely to feel discouraged during the adjustment phase; people who understand the dose escalation curve tend to stay the course through to the months where results compound. That's not just anecdote, it's reflected in the adherence patterns observed in the clinical trials themselves. If you're also considering supplementary options, our page on whether B12 injections cause weight loss sets out what the evidence does and does not support for that approach.

If you're weighing up which injection suits your situation better, our page comparing whether weight loss injections work sits the evidence alongside the practicalities. For questions about longer-term outcomes and the factors that affect individual response, the how long does it take guide goes deeper on sustained use. Both medicines are prescription-only and require clinical assessment, a prescriber decides whether treatment is appropriate for you, and at what dose to begin. If you'd like that assessment, you can check your eligibility with our clinical team.